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Alternative splicing and proteolytic processing of VEGFs generate proteins with distinct physiological roles.
In this issue of Structure, Parker et al. show that proteolysis of an isoform of the VEGF-C coreceptor Nrp2
produces a soluble receptor that inhibits VEGF-C/Nrp2 interactions.For the past 25 years, the five vascular
endothelial growth factors (VEGFs) have
received considerable scientific scrutiny
aimed at unraveling their complex roles
in endothelial cell function (Olsson et al.,
2006). In particular, VEGF-A/B/C/D and
placental growth factor have unique
and overlapping roles in the signaling
pathways that control the development
of the vascular system during embryo-
genesis (vasculogenesis) as well as the
development of new blood and lymphatic
vessels (angiogenesis and lymphangio-
genesis). These secreted glycoproteins
form disulfide-bonded dimers that signal
across the cell membrane principally
through three related receptor tyrosine
kinases called VEGF receptors (VEGFRs)
to shape the vascular and lymphatic
systems. Medically, the discovery that
sustained tumor growth requires the pres-
ence of an adequate blood supply or that
cancer cells metastasize using blood
and lymphatic vessels has spurred the
design of VEGF-targeted therapies as an
integral part of the cancer-fighting arsenal
(Ellis and Hicklin, 2008; Stacker et al.,
2002; Vasudev and Reynolds, 2014).
Our understanding of VEGF-based
signaling is further complicated by the
existence of several variants of the growth
factors that are created by alternative
splicing and proteolytic processing. The
cystine-knot region of the VEGF antipar-
allel dimer harboring the VEGFR-binding
site is left unchanged by these splicing
and proteolytic events, but they create
alternative C-termini that modify the
abilities of VEGFs to interact with essen-
tial coreceptors such as heparin sulfate
proteoglycans as well as the type I trans-
membrane proteins neuropilin-1 and 2610 Structure 23, April 7, 2015 ª2015 Elsevie(Nrp1 and 2) (Olsson et al., 2006). Neuro-
pilins are the consummate coreceptors,
functioning in VEGF signaling as well as
in semaphorin/plexin signaling, which
plays a critical role in manifold tissue
patterning events (Parker et al., 2012a).
In particular, VEGF-C signals through
VEGFR-3 and Nrp2 to mediate lymphan-
giogenesis (Xu et al., 2010) and nrp2-null
mice exhibit defective lymphangiogenesis
(Yuan et al., 2002) (Figure 1A). Moreover,
blocking of VEGF-C binding to Nrp2
using a monoclonal antibody impairs
cancer cell metastasis, suggesting that
inhibitors of VEGF-C/Nrp2 interactions
might become important treatment op-
tions for cancer (Caunt et al., 2008).
The extracellular regions of neuropilins
include two coagulation factor domains
called b1 and b2 that form an integral
structural unit owing to extensive inter-
domain interactions. Interestingly, the
splicing or processing events that confer
Nrp1/2 binding to VEGFs result in the
presence of a C-terminal arginine residue
(Parker et al., 2012a). In previous pub-
lished works, Craig Vander Kooi and col-
leagues identified a site in the b1 domain
that accommodates such C-terminal
arginine residues and provided a struc-
tural basis for the binding of VEGF-A165
to Nrp1 (Parker et al., 2012b). In this issue
of Structure, the Vander Kooi lab expand
their structural analyses to explain how
VEGF-C interacts specifically with Nrp2
and discover that a secreted splice form
of Nrp2 might function as endogenous
inhibitor of VEGF-C signaling (Parker
et al., 2015). Consistent with the structure
of VEGF-A165 bound to Nrp1, the C-termi-
nal arginine of VEGF-C fits into a pocket
in which Nrp2 residues form an extensiver Ltd All rights reservednetwork of hydrogen bonds with the argi-
nine side chain as well as the C-terminal
carboxylate. A loop found in the b1
domain of Nrp2 and in Nrp1 walls up one
side of the cleft to prevent binding of any
residue that is not in C-terminal position.
Taken together with the structure of
the VEGF-A165 bound to Nrp1 (Parker
et al., 2012b), the VEGF-C,Nrp2 complex
structure essentially settles the question
of specific VEGF recognition by Nrps.
Parker et al. (2015) also report the
characterization of a secreted form of
Nrp2 that antagonizes VEGF-C signaling
(Figure 1B). In the splice form s9Nrp2,
a premature stop codon is inserted in
the sequence encoding the b2 domain,
resulting in the expression of a protein
that lacks important structural features
necessary to produce a correctly folded
b2 domain, but leaving the b1 domain
intact. Thus, Parker et al. reasoned that
if s9Nrp2 is functional, it might retain
VEGF-C-binding properties and poten-
tially function as a VEGF-C inhibitor.
Strikingly, expression of a fragment of
s9Nrp2 with the b1 domain and the
truncated b2 domain (called s9Nrp2
B)
yielded a protein that was smaller than
what could be expected from the primary
sequence because of proteolytic pro-
cessing. A cysteine residue that forms
a conserved disulfide bridge in intact
coagulation factor domains is left
unpaired after splicing and proteolysis
and now participates in a disulfide bridge
with the unpaired cysteine from another
s9Nrp2
B to create a disulfide-bonded
dimer. Structural and biochemical ana-
lyses indicated that the b2 domain stub
folds into an a helix that is an integral
part of the dimer interface. The two
Figure 1. Physiological Roles of VEGF-C and Its Sequestration by a
Proteolyzed Isoform of Nrp2
(A) VEGF-C binds to VEGFR3 andNrp2 tomediate angiogenesis and lymphan-
giogenesis. The cystine-knot region of VEGF-C (yellow) associates with
VEGFR-3 while its C-terminal arginine residue mediates specific binding to
Nrp2.
(B) s9Nrp2
B simultaneously engages the C-terminal arginine residues in the
VEGF-C homodimer to sequester the growth factor and block Nrp2-based
VEGF-C signaling. The formation of s9Nrp2
B,VEGF-C complexes has no effect
on the binding of VEGF-C to VEGFR3.
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PreviewsVEGF-C-binding pockets are
separated by 71 A˚ in the
s9Nrp2
B homodimers, which
is almost an exact match to
the 68 A˚ that separate the
C-termini in VEGF-C dimers.
This finding suggests that the
two Nrp2-binding sites in the
VEGF-C dimer can simulta-
neously engage s9Nrp2
B.
Consistent with this ob-
servation, s9Nrp2
B inhibits
VEGF-C binding to Nrp2 with
an IC50 of 250 nM compared
to 1.5 mM for the Nrp2 b1
domain alone. However,
s9Nrp2
B has no effect on
the formation of VEGF-
C,VEGFR-3 complexes.
Because VEGF-C and Nrp2
have been linked to the
aggressiveness of prostate
cancer, the effect of s9Nrp2
B
was tested in a sphere-forma-
tion assay and resulted in sig-
nificant reduction of prostato-
sphere formation. This final
finding thus confirms thehunch of Parker and colleagues that
s9Nrp2 might antagonize VEGF-C/Nrp2
signaling (Parker et al., 2015).
Moving forward, the physiological role
of s9Nrp2 during the development of the
vascular and lymphatic systems remains
to be determined. It is also unclear which
protease cleaves s9Nrp2 or if this process
is regulated. However, the most exciting
questions center on the development of
s9Nrp2
B-based therapeutics. Importantly,because nrp2-null mice display normal
angiogenesis, such therapeutics might
not have the side effect associated with
inhibitors that target the VEGF/VEGFR
signaling pathway, yet it remains unclear
whether s9Nrp2
B can be engineered to
bind more tightly to VEGF-C or associate
with additional VEGF family members.
Furthermore, the extent to which
s9Nrp2
B might inhibit metastasis is un-
known. Transforming s9Nrp2
B into anStructure 23, April 7, 2015 ª2015 Elseoptimal therapeutic is a long
way off, but the work under-
taken by the Vander Kooi lab
might have just put us on the
trail of a potent anticancer
drug.
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